Limits...
High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.

Yang C, Nan H, Ma J, Jiang L, Guo Q, Han L, Zhang Y, Nan K, Guo H - Breast Cancer (Auckl) (2015)

Bottom Line: Downregulation of p57(Kip2) is involved in tumor progression, and S-phase kinase-associated protein 2 (Skp2) is an E3 ligase that regulates a variety of cell cycle proteins.In addition, univariate analysis showed that Skp2, p57(Kip2), histological grade, lymph node metastasis, and estrogen and progesterone receptors (ER and PR) were all associated with DFS, and multivariate analysis revealed that lymph node metastasis and Skp2 were independent prognostic biomarkers.Half-life and immunoprecipitation (IP) experiments indicated that Skp2 directly interacts with p57(Kip2) and promotes its degradation, rather than its mutant p57(Kip2) (T310A).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shannxi, P. R. China.

ABSTRACT
Downregulation of p57(Kip2) is involved in tumor progression, and S-phase kinase-associated protein 2 (Skp2) is an E3 ligase that regulates a variety of cell cycle proteins. However, the prognostic value of p57(Kip2) and its correlation with Skp2 in breast cancer have not been fully elucidated. Here we report our study on the expression of p57(Kip2) and Skp2 in 102 breast cancer patients by immunohistochemistry, and analysis of clinicopathologic parameters in relation to patient prognosis. The expression of p57(Kip2) was negatively associated with Skp2 expression in breast cancer (r = -0.26, P = 0.009). Kaplan-Meier analysis indicated that both high Skp2 and low p57(Kip2) correlated with poor disease-free survival (DFS) (P = 0.05), and a group with the combination of high Skp2/low p57(Kip2) demonstrated even worse DFS (log-rank = 21.118, P < 0.001). In addition, univariate analysis showed that Skp2, p57(Kip2), histological grade, lymph node metastasis, and estrogen and progesterone receptors (ER and PR) were all associated with DFS, and multivariate analysis revealed that lymph node metastasis and Skp2 were independent prognostic biomarkers. The correlation between p57 and Skp2 was further demonstrated in multiple breast cancer cell lines and cell cycle phases. Half-life and immunoprecipitation (IP) experiments indicated that Skp2 directly interacts with p57(Kip2) and promotes its degradation, rather than its mutant p57(Kip2) (T310A). Overall, our findings demonstrate that Skp2 directly degrades p57(Kip2), and an inverse correlation between these proteins (high skp2/low p57(Kip2)) is associated with poor prognosis in breast cancer. Thus, our results indicate a combined prognostic value of these markers in breast cancer diagnosis and treatment.

No MeSH data available.


Related in: MedlinePlus

Representative slides demonstrating expression of p57Kip2 and Skp2 in breast cancer tissues. Tumor cells exhibit (A) high (×200) and (C) low (×200) Skp2 nuclear/cytoplasmic staining and (B) high (×200) and (D) low (×200) p57Kip2 stains in breast cancer tissues.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4525793&req=5

f1-bcbcr-suppl.1-2015-013: Representative slides demonstrating expression of p57Kip2 and Skp2 in breast cancer tissues. Tumor cells exhibit (A) high (×200) and (C) low (×200) Skp2 nuclear/cytoplasmic staining and (B) high (×200) and (D) low (×200) p57Kip2 stains in breast cancer tissues.

Mentions: To assess the expression of Skp2 and p57Kip2, immunohistochemistry was performed in a series of 102 primary human breast cancers. Typical Skp2 and p57Kip2 staining is shown in Figure 1. Forty-one (40.2%) patients expressed high levels of Skp2 and low levels of p57Kip2, 24 (23.5%) patients expressed low levels of Skp2 and high levels of p57Kip2, and 15 (14.7%) patients expressed high levels of both Skp2 and p57Kip2, while 22 (21.6%) patients expressed low levels of both proteins. An inverse correlation was found between Skp2 and p57Kip2 expression in breast cancer (r = −0.26, P = 0.009) (Table 1).


High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.

Yang C, Nan H, Ma J, Jiang L, Guo Q, Han L, Zhang Y, Nan K, Guo H - Breast Cancer (Auckl) (2015)

Representative slides demonstrating expression of p57Kip2 and Skp2 in breast cancer tissues. Tumor cells exhibit (A) high (×200) and (C) low (×200) Skp2 nuclear/cytoplasmic staining and (B) high (×200) and (D) low (×200) p57Kip2 stains in breast cancer tissues.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4525793&req=5

f1-bcbcr-suppl.1-2015-013: Representative slides demonstrating expression of p57Kip2 and Skp2 in breast cancer tissues. Tumor cells exhibit (A) high (×200) and (C) low (×200) Skp2 nuclear/cytoplasmic staining and (B) high (×200) and (D) low (×200) p57Kip2 stains in breast cancer tissues.
Mentions: To assess the expression of Skp2 and p57Kip2, immunohistochemistry was performed in a series of 102 primary human breast cancers. Typical Skp2 and p57Kip2 staining is shown in Figure 1. Forty-one (40.2%) patients expressed high levels of Skp2 and low levels of p57Kip2, 24 (23.5%) patients expressed low levels of Skp2 and high levels of p57Kip2, and 15 (14.7%) patients expressed high levels of both Skp2 and p57Kip2, while 22 (21.6%) patients expressed low levels of both proteins. An inverse correlation was found between Skp2 and p57Kip2 expression in breast cancer (r = −0.26, P = 0.009) (Table 1).

Bottom Line: Downregulation of p57(Kip2) is involved in tumor progression, and S-phase kinase-associated protein 2 (Skp2) is an E3 ligase that regulates a variety of cell cycle proteins.In addition, univariate analysis showed that Skp2, p57(Kip2), histological grade, lymph node metastasis, and estrogen and progesterone receptors (ER and PR) were all associated with DFS, and multivariate analysis revealed that lymph node metastasis and Skp2 were independent prognostic biomarkers.Half-life and immunoprecipitation (IP) experiments indicated that Skp2 directly interacts with p57(Kip2) and promotes its degradation, rather than its mutant p57(Kip2) (T310A).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shannxi, P. R. China.

ABSTRACT
Downregulation of p57(Kip2) is involved in tumor progression, and S-phase kinase-associated protein 2 (Skp2) is an E3 ligase that regulates a variety of cell cycle proteins. However, the prognostic value of p57(Kip2) and its correlation with Skp2 in breast cancer have not been fully elucidated. Here we report our study on the expression of p57(Kip2) and Skp2 in 102 breast cancer patients by immunohistochemistry, and analysis of clinicopathologic parameters in relation to patient prognosis. The expression of p57(Kip2) was negatively associated with Skp2 expression in breast cancer (r = -0.26, P = 0.009). Kaplan-Meier analysis indicated that both high Skp2 and low p57(Kip2) correlated with poor disease-free survival (DFS) (P = 0.05), and a group with the combination of high Skp2/low p57(Kip2) demonstrated even worse DFS (log-rank = 21.118, P < 0.001). In addition, univariate analysis showed that Skp2, p57(Kip2), histological grade, lymph node metastasis, and estrogen and progesterone receptors (ER and PR) were all associated with DFS, and multivariate analysis revealed that lymph node metastasis and Skp2 were independent prognostic biomarkers. The correlation between p57 and Skp2 was further demonstrated in multiple breast cancer cell lines and cell cycle phases. Half-life and immunoprecipitation (IP) experiments indicated that Skp2 directly interacts with p57(Kip2) and promotes its degradation, rather than its mutant p57(Kip2) (T310A). Overall, our findings demonstrate that Skp2 directly degrades p57(Kip2), and an inverse correlation between these proteins (high skp2/low p57(Kip2)) is associated with poor prognosis in breast cancer. Thus, our results indicate a combined prognostic value of these markers in breast cancer diagnosis and treatment.

No MeSH data available.


Related in: MedlinePlus